Literature DB >> 7114807

Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome.

P C Dau, E H Denys.   

Abstract

Five patients with Eaton-Lambert syndrome (ELS) without associated malignancy were first treated by plasmapheresis alone, and subsequently by plasmapheresis combined with prednisone and azathioprine therapy. Three of the five were also treated by the immunosuppressive drugs alone. Although all three therapeutic regimens resulted in some clinical and electromyographic (EMG) improvement, the greatest improvement was seen during plasmapheresis combined with prednisone and azathioprine. The initial evoked compound muscle action potential (CMAP) increased during treatment in all patients, while facilitation of the initial CMAP by tetanic stimulation decreased. Overall, the EMG decrement elicited at 2 Hz lessened in four of the five patients. Serious complications probably attributable to guanidine toxicity developed in three patients: two had renal failure and one had gastrointestinal and urinary tract bleeding. Our results suggest that immunosuppressive therapy may have a place in the management of ELS and that circulating factors such as autoantibody may participate in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114807     DOI: 10.1002/ana.410110604

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

Review 1.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

Review 3.  Plasma exchange in neurological diseases.

Authors:  P O Behan; W M Behan
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

Review 4.  [Therapeutic plasma exchange 1996].

Authors:  U Weber; W Riegel; H Köhler
Journal:  Med Klin (Munich)       Date:  1997-10-15

5.  Autonomic dysfunction in Lambert-Eaton myasthenic syndrome.

Authors:  S A Waterman
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

6.  Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Authors:  D A Ingram; G R Davis; M S Schwartz; M Traub; A C Newland; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

Review 7.  Paraneoplastic syndromes of the nervous system.

Authors:  G Palma
Journal:  West J Med       Date:  1985-06

Review 8.  The Lambert-Eaton myasthenic syndrome.

Authors:  A F Carpentier; J Y Delattre
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 10.817

Review 9.  Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Authors:  Nina A Ran; Aimee S Payne
Journal:  F1000Res       Date:  2017-01-27

Review 10.  Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome.

Authors:  Arsalan Anwar; Sidra Saleem; Mirza Fawad Ahmed; Sara Ashraf; Sameen Ashraf
Journal:  Cureus       Date:  2019-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.